Imagen de Portada

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Richie Manikat, Aijaz Ahmed, Donghee Kim
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
por: Richie Manikat, et al.
Publicado: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
por: Nipun Verma, et al.
Publicado: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
por: Donghee Kim, et al.
Publicado: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
por: Nabil Noureddin, et al.
Publicado: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
por: María Hernández‐Pérez, et al.
Publicado: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
por: Mohamad Jamalinia, et al.
Publicado: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
por: Rocio Enriquez, et al.
Publicado: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
por: Yewan Park, et al.
Publicado: (2024)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
por: Angelo Armandi, et al.
Publicado: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
por: Mohamed I. Elsaid, et al.
Publicado: (2024)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
por: Donghee Kim, et al.
Publicado: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
por: Donghee Kim, et al.
Publicado: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
por: Donghee Kim, et al.
Publicado: (2025)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
por: Carolin V. Schneider, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
por: Manya Prasad, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
por: Samer Gawrieh, et al.
Publicado: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
por: Wenjun Meng, et al.
Publicado: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
por: Antonio De Vincentis, et al.
Publicado: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
por: Shusuke Kumazaki, et al.
Publicado: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
por: Parminder Kaur, et al.
Publicado: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
por: Lukas Hartl, et al.
Publicado: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
por: Sung Won Chung, et al.
Publicado: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
por: Pojsakorn Danpanichkul, et al.
Publicado: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
por: Pojsakorn Danpanichkul, et al.
Publicado: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
por: Nipun Verma, et al.
Publicado: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
por: Victoria T. Kronsten, et al.
Publicado: (2024)

Review article: Oesophageal disorders in chronic liver disease
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
por: Rui Zhang, et al.
Publicado: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
por: Deepak Joshi, et al.
Publicado: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
por: Zhuo Li, et al.
Publicado: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation
por: Sara J. Harris, et al.
Publicado: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
por: C. Stephens
Publicado: (2024)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
por: Raj Vuppalanchi, et al.
Publicado: (2024)